Nevin İLHAN, Bengü ÇOBANOĞLU, Tevfik TURGUT, Mehmet Hamdi MUZ, Gamze KIRGIL, Figen DEVECİ, Ersin Şükrü ERDEN

Ratlarda bleomisin ile oluşturulan akciğer fibrozisinde erdosteinin inflamasyon ve fibrozis üzerine etkileri

Bleomisin (BLM) uygulaması ile ratlarda akciğer fibrozisi oluşturarak, akut inflamatuvar ve fibrotik fazlarda akciğer dokusunda ve bronkoalveolar lavaj (BAL) sıvısında bazı kemokin ve sitokinlerin düzeyini, akciğer dokusunda oluşan histopatolojik değişiklikleri ve antioksidan etkisi olan erdosteinin akut inflamatuvar değişiklikler ve fibrozis üzerine etkilerini araştırmayı amaçladık. Çalışmaya Wistar tipi 45 erkek rat alındı. 0.günde; kontrol grubuna (grup 1, n=15) intratrakeal (i.t.) salin, BLM (grup 2, n=15) ve erdostein grubuna (grup 3, n=15) i.t. BLM (7.5 U/kg) uygulandı. Erdostein grubuna BLM uygulamasında 2 gün önce peroral 10 mg/kg/gün erdostein başlandı. Tüm gruplarda 0., 14. ve 29. günde 5’er adet rat sakrifiye edilerek BAL yapıldı. BAL’da malondialdehit (MDA), makrofaj inflamatuar protein 1 alfa (MIP-1α), MIP-2 düzeylerinin ölçümü ve inflamatuvar hücre sayımı, akciğer dokusunda hidroksiprolin ölçümü ve histopatolojik inceleme yapıldı. BLM grubu ile karşılaştırıldığında erdostein grubunun BAL sıvısında nötrofil, MIP-1α, MIP-2, MDA düzeylerinin ve akciğer dokusunda hidroksiprolin (OH-P) içeriğinin akut inflamatuvar fazda (14. gün) (sırasıyla, p

Effects of erdosteine on inflammation and fibrosis in rats with pulmonary fibrosis induced by bleomycin

We aimed to investigate the levels of some chemokines, inflammatory cell counts in bronchoalveolar lavage fluid (BALF), histopathological changes in lung tissue, to determine the effect of erdosteine on acute inflammatory changes and fibrosis in a rat fibrosis model induced by Bleomycine (BLM). Forty-five Wistar male rats were taken into the study. On day 0, intra tracheal (i.t.) saline to control group (group 1, n=15), i.t bleomycine 7.5 U/kg to bleomycine (group 2, n=15) and erdostein group (group 3, n=15) was administered. In group 3, oral erdostein (10 mg/kg/day) was applied two days before bleomycine. On day 0, 14, and 29. five rats in each groups were sacrificed, BALF was performed. Malonyldialdehyde (MDA), macrophage inflammatory protein 1 alpha (MIP-1α), MIP-2 levels in BALF, hydroxyproline levels in lung tissue were measured. Histopathological examination was performed. When BLM group compared to erdostein group, the levels of MDA, MIP-1α, MIP-2, and neutrophil counts, the hydroxyproline (OH-P) level of lung tisssue were decreased in erdostein group on acute inflammatory phase (day 14) (p

PDF

___

1. Goldstein RH, Fine A. Potential therapeutic initiatives for fibrogenic lung disease. Chest 1995; 108: 848-55.
2. Sausville EA, Stein RW, Peisach J, Horwitz SB. Properties and products of degradation of DNA by bleomycin and iron (II). Biochemistry 1978; 17: 2746-54.
3. Galvan L, Huang CH, Prestayko AW, et al. Inhibition of bleomycine-induced DNA breakage by superoxide dismutase. Cancer Res 1981; 41: 5103-6.
4. Cunningham ML, Ringrose PS, Lokesh BR. Inhibition of the genotoxicity of bleomicin by superoxide dismutase. Mutat Res 1984; 135: 199-202.
5. Hagiwara S, Ishii Y, Kitamura S. Aerolized administration of N-acetylcysteine attenuates lung fibrosis induced by bleomicin in mice. Am J Respir Crit Care Med 2000;162: 225-31.
6. Crystal RG, Bitterman PB, Rennard SI, et al. Interstitial lung diseases unknown cause: Disorders characterized by chronic inflammation of the lower respiratory tract. N Engl J Med 1984; 310: 154-66.
7. Olivieri D, Del-Donno M, Casalini A, et al. Activity of erdosteine on mucociliary transport in patients affected by chronic bronchitis. Respiration 1991; 58: 91-4.
8. Biagi GL, Fregnan GB, Gazzani G, Vandoni G. Erdosteine protection from cigarette smoke-induced loss of α1-antitrypsin activity in rat lungs. Int J Clin Pharmacol Ther Toxicol 1989; 27: 235-7.
9. Inglesi M, Nicola M, Fregnan GB, et al. Synthesis and free radical scavening properties of the enantiomers of erdosteine. Farmaco 1994; 40: 703-8.
10. Vagliasindi M, Fregnan GB. Erdosteine protection against cigarette smoking-induced functional antiprotease deficiency in human bronchiolo-alveolar structures. Int J Clin Pharmacol Ther Toxicol 1989; 27: 238-41.
11. Ozyurt H, Söğüt S, Yildirim Z, et al. Inhibitory effect of caffeic acid phenethyl ester on bleomycine-induced lung fibrosis in rats. Clin Chim Acta 2004; 339: 65-75.
12. Boyaci H, Maral H, Turan G, et al. Effects of erdosteine on bleomycin-induced lung fibrosis in rats. Mol Cell Biochem 2006; 281: 129-37.
13. Wang HD, Yamaya M, Okinaga S, et al. Bilirubin ameliorates bleomycin-induced pulmonary fibrosis in rats. Am J Respir Crit Care Med 2002; 165: 406-11.
14. Wang YH, Bai CX, Hong QY, Chen J. Anti-inflammatory effect of methoxyphenamine compound in rat model of chronic obstructive pulmonary disease. Acta Pharmacol Sin 2003; 24: 1324-7.
15. Agarwal R, Chase SD. Rapid, fluorimetric-liquid chromatographic determination of malondialdehyde in biological samples. J Chromatogr B Analyt Technol Biomed Life Sci 2002; 775: 121-6.
16. Woessner JF. The determination of hydroxyproline in tissue and protein samples containing small proportions of this imino acid. Arch Biochem Biophys 1961; 93: 440-7.
17. Ashcroft T, Simpson JM, Timbrell V. Simple method of estimating severity of pulmonary fibrosis on a numerical scale. J Clin Pathol 1988; 41: 467-70.
18. Gurujeyalakshmi G, Wang Y, Giri SN. Suppression of bleomycin-induced nitric oxide production in mice by taurine and niacin. Nitric Oxide 2000; 4: 399-411.
19. Yildirim Z, Kotuk M, Iraz M, et al. Attenuation of bleomycin- induced lung fibrosis by oral sulfydryl containing antioxidants in rats: Erdosteine and N-acetylcysteine. Pulm Pharmacol Ther 2005; 18: 367-73.
20. Serrano-Mollar A, Closa D, Prats N, et al. In vivo antioxidant treatment protects against bleomycin-induced lung damage in rats. Br J Pharmacol 2003; 138: 1037-48.
21. Smith RE, Strieter RM, Zhang K, et al. A role for C-C chemokines in fibrotic lung disease. J Leukoc Biol 1995; 57:782-7.
22. Keane MP, Belperio JA, Moore TA, et al. Neutralization of the CXC chemokine macrophage inflammatory protein-2 attenuates bleomycin-induced pulmonary fibrosis. J Immunol 1999; 162: 5511-8.
23. Theodore J, Standiford TJ, Rolfe MW, et al. Macrophage inflammatory protein-1α expression in interstitial lung disease. J Immunol 1993; 151: 2852-63.
24. Yara S, Kawakami K, Kudeken N, et al. FTS reduces bleomycin- induced cytokine and chemokine production and inhibits pulmonary fibrosis in mice. Clin Exp Immunol 2001; 124: 77-85.
25. Sayman S, Meyancı Köksal G, Erdamar S ve ark. Tavşanlarda akut akciğer hasarında nedokromil sodyumun tedavideki yerinin araştırılması. GKD Anest Yoğ Bak Dern Derg 2003; 9: 52-5.
26. Meyancı G, Arıcıoglu F, Oz H, Aydemir A. The effects of intratracheal dexamethasone on lipid peroxidation in acute lung injury. Cerrahpaşa J Med 2001; 32: 20-4.
27. Yildirim Z, Sogut S, Odaci E, et al. Oral erdosteine administration attenuates cisplatin-induced renal tubular damage in rats. Pharmacol Res 2003; 47: 149-56.
28. Yagmurca M, Fadillioglu E, Erdogan H, et al. Erdosteine prevents doxorubicin-induced cardiotoxicitiy in rats. Pharmacol Res 2003; 48: 377-82.
29. Ege E, Ilhan A, Gurel A, et al. Erdosteine amilorates neurological outcome and oxidative stres due to iscehemia/ reperfusion injury in rabbit spinal cord. Eur J Vasc Endovasc Surg 2004; 28: 379-86.
30. Dechant KL, Noble S. Erdosteine. Drugs 1996; 52: 875-81.
31. Tamagawa K, Taooka Y, Maeda A, et al. Inhibitory effects of a lecithinized superoxide dismutase on bleomycin-induced pulmonary fibrosis in mice. Am J Respir Crit Care Med 2000; 161: 1279-84.
32. Hong JS, Ko HH, Han ES, Lee CS. Inhibition of bleomycin- induced cell death in rat alveolar macrophages and human lung epithelial cells by ambroxol. Biochem Pharmacol 2003; 66: 1297-306.
33. Sleijefer S. Bleomycin-induced pneumonitis. Chest 2001; 120: 617-24.
34. Cortijo J, Cerda-Nicolas M, Serrano A, et al. Attenuation by oral N-acetylcysteine of bleomycin-induced lung injury in rats. Eur Respir J 2001; 17: 1228-35.
35. Serrano-Mollar A, Closa D, Cortijo J, et al. P-selectin upregulation in bleomycin-induced lung injury in rats: Effect of N-acetylcysteine. Thorax 2002; 57: 629-34.
36. Mata M, Ruiz A, Cerda M, et al. Oral N-acetylcysteine reduces bleomycin-induced lung damage and mucin Muc-5ac expression in rats. Eur Respir J 2003; 22: 900-5.
37. Sogut S, Ozyurt H, Akyol O, et al. Protection of erdosteine on bleomycine-induced lung fibrosis in rats. Eur J Pharmacol 2004; 494: 213-20.